|Articles|September 10, 2020
- Pharmaceutical Executive-09-01-2020
- Volume 40
- Issue 9
Pharmaceutical Executive, September 2020 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive September 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 5 years ago
Our Launch-Time Menuabout 5 years ago
Drug Launch: Winning the Evidence Battleabout 5 years ago
COVID Causes Pharma Marketers to Watch TVabout 5 years ago
Succession Plan: Skyriziabout 5 years ago
New Standards for First-to-Launch Playersabout 5 years ago
(O)mega Opportunity: Vascepaabout 5 years ago
Educational Mission: Oxbrytaabout 5 years ago
First in Class: Spravatoabout 5 years ago
One Time for Lifetime: Zolgensmaabout 5 years ago
Biopharma Capital Markets Sizzle in 2020Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Is FDA Streamlining Regulations in the Biosimilar Space?
2
Eli Lilly’s Jaypirca Achieves Primary Endpoint in Head-to-Head Phase III Study Against Imbruvica Treating CLL/SLL
3
Carvykti Displays Sustained Remissions in Early Use for Relapsed or Refractory Multiple Myeloma
4
When Borders Become Bottlenecks: How Pharma Should Adapt to the New Geopolitical Lens
5
